ストックスクリーナーアプリを入手
318.89
0.26%
-0.83
プレマーケット:
316.51
-2.38
-0.75%
Penumbra Inc (PEN) 最新ニュース
The Technical Signals Behind (PEN) That Institutions Follow - Stock Traders Daily
Anaconda Biomed raises $56m for catheter portfolio’s advance - Yahoo Finance
Penumbra stock reports 14.9 percent revenue growth - AD HOC NEWS
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
ETFs Investing in Penumbra, Inc. Stocks - TradingView
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential - DirectorsTalk Interviews
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation - AD HOC NEWS
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high - AD HOC NEWS
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
Reasons to Retain Penumbra Stock in Your Portfolio for Now - Eastern Progress
Mechanical Clot Engagement Option for CAVT Thrombectomy Now Available - dicardiology.com
Penumbra Inc. (PEN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Penumbra, Inc. (PEN) Stock Analysis: Navigating Growth With A 13.88% Potential Upside - DirectorsTalk Interviews
Penumbra, Inc. (PEN): Growth Potential Amidst Analyst Consensus And Market Dynamics - DirectorsTalk Interviews
Price to earnings forward of Penumbra, Inc. – NYSE:PEN - TradingView
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
BSP:P2NB34 Enterprise Value: R$-100 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 Shareholder Yield %: 0.05% | Fairly Valued - GuruFocus
BSP:P2NB34 Revenue: R$7,963 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 GF Value: R$57.41 | Fairly Valued - GuruFocus
BSP:P2NB34 ROCE %: 10.74% | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026) - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
BSP:P2NB34 3-Year EPS without NRI Growth Rate: 188.40% — 5 - GuruFocus
Penumbra (BSP:P2NB34) Land And Improvements : R$0 Mil (As of Jun. 2026) - GuruFocus
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
BSP:P2NB34 Other Current Assets: R$268 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Total Long-Term Assets : R$3,231 Mil (As of Jun. 2026) - GuruFocus
BSP:P2NB34 Net Income: R$853 Mil | Fairly Valued - GuruFocus
BSP:P2NB34 FCF Yield %: 1.79 — 2457% Above Median - GuruFocus
BSP:P2NB34 Market Cap: R$2,172 Mil | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) 12-1 Month Momentum % : N/A% (As of Sep. 05, 2026) - GuruFocus
BSP:P2NB34 3-Year RORE %: 46.88 | Fairly Valued - GuruFocus
BSP:P2NB34 PE Ratio (TTM): 2.55 — 99% Below Median - GuruFocus
Penumbra (BSP:P2NB34) 3-1 Month Momentum % : N/A% (As of Sep. 04, 2026) - GuruFocus
BSP:P2NB34 Net-Net Working Capital: R$75.32 | Fairly Valued - GuruFocus
Penumbra (BSP:P2NB34) Other Income (Minority Interest) : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
Penumbra (BSP:P2NB34) Repurchase of Stock : R$0 Mil (TTM As of Jun. 2026) - GuruFocus
BSP:P2NB34 Forward PE Ratio: 1.72 | Fairly Valued - GuruFocus
Penumbra Inc Stock Operating Data - GuruFocus
BSP:P2NB34 Pre-Tax Income: R$1,082 Mil | Fairly Valued - GuruFocus
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - DirectorsTalk Interviews
Penumbra Inc. (PEN) Peer Comparison – Compare with Others - Value Research
Penumbra Inc. (PEN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Penumbra Inc. (PEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Incuvate Files Patent Infringement Lawsuit Against Penumbra - The Manila Times
Penumbra, Inc. (PEN) Stock Analysis: Exploring Growth Potential And Market Position - DirectorsTalk Interviews
Penumbra (PEN) Financial Update: EPS Does Not Reach the Reported Estimate at the Close; Investor Response: Shares Finish 0.43% DownAnnual Report - careplusvn.com
Trillium Asset Management LLC Acquires New Stake in Penumbra, Inc. $PEN - MarketBeat
BlackRock Inc. Invests $1.36 Billion in Penumbra, Inc. $PEN - MarketBeat
Incuvate Says Penumbra Infringed Blood Clot Detection System (1) - Bloomberg Law News
Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Penumbra (NYSE: PEN) grants president 3,060 RSUs with multi-year vesting - Stock Titan
Penumbra (PEN) Results at a Glance: Reported EPS Misses Expectations for This Review; Trading-Day Reaction: The Share Price Sheds 0.74% in the Available RecordForward Guidance Trends - vinanet.vn
NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN - MarketBeat
Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN - MarketBeat
Penumbra, Inc. (PEN) Stock Analysis: Exploring a 10.65% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Fidelity Advisor Mid Cap II Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Alberta Investment Management Corp Invests $10.46 Million in Penumbra, Inc. $PEN - MarketBeat
Neurothrombectomy Devices Market Size, Share | Growth [2034] - fortunebusinessinsights.com
S&CO Inc. Takes Position in Penumbra, Inc. $PEN - MarketBeat
Technical Reactions to PEN Trends in Macro Strategies - Stock Traders Daily
Penumbra, Inc.: Financial Data Forecasts Estimates and Expectations | PEN | US70975L1070 - marketscreener.com
Penumbra (PEN) Holds Steady Near $326.75 as Traders Eye Key Support and ResistanceRetail Driven Moves - careplusvn.com
Barclays PLC (PEN) discloses 2.34M-share beneficial stake in Penumbra Inc - Stock Titan
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors? - webull.com
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Singapore
1.51%
0.97%
大文字化:
|
ボリューム (24 時間):